TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Kolodziej, Lauren E ^a   Lodolce, James P ^a,c   Chang, Jonathan E ^a   Schneider, Jeffrey R ^a   Grimm, Wesley A ^a   Bartulis, Sarah J ^a   Zhu, Xiaorong ^a   Messer, Jeannette S ^a   Murphy, Stephen F ^a   Reddy, Nishith ^b   Turner, Jerrold R ^a   Boone, David L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b ILLINOIS MATHEMATICS AND SCIENCE ACADEMY   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN LIGHT CHAIN KINASE; OCCLUDIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG; CYSTEINE PROTEINASE; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, HUMAN; TNFAIP3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CELL; INTESTINE EPITHELIUM; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TIGHT JUNCTION; UBIQUITINATION; ANIMAL; CELL LINE; CELL STRAIN HCT116; GENETICS; INTESTINE MUCOSA; METABOLISM; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ANIMALS; CELL LINE; CYSTEINE ENDOPEPTIDASES; HCT116 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; NUCLEAR PROTEINS; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054834748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026352     Document Type: Article

References (66)

1. Shen L, Weber CR, Raleigh DR, Yu D, Turner JR, (2011) Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol 73: 283-309.
2. Sartor RB, (2006) Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3: 390-407.
3. Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, et al. (1999) Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 5: 262-270.
4. Hermiston ML, Gordon JI, (1995) Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 270: 1203-1207.
5. Kaser A, Zeissig S, Blumberg RS, (2010) Inflammatory bowel disease. Annu Rev Immunol 28: 573-621.
6. Arrieta MC, Madsen K, Doyle J, Meddings J, (2009) Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut 58: 41-48.
7. Gerova VA, Stoynov SG, Katsarov DS, Svinarov DA, (2011) Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test. World J Gastroenterol 17: 2211-2215.
8. Welcker K, Martin A, Kolle P, Siebeck M, Gross M, (2004) Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res 9: 456-460.
9. Hollander D, (1999) Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep 1: 410-416.
10. Turner JR, (2006) Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 169: 1901-1909.
11. Turner JR, (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9: 799-809.
12. Shen L, Weber CR, Turner JR, (2008) The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state. J Cell Biol 181: 683-695.
13. Murakami T, Felinski EA, Antonetti DA, (2009) Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem 284: 21036-21046.
14. Marchiando AM, Shen L, Graham WV, Weber CR, Schwarz BT, et al. (2010) Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol 189: 111-126.
15. Su L, Shen L, Clayburgh DR, Nalle SC, Sullivan EA, et al. (2009) Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 136: 551-563.
16. Blair SA, Kane SV, Clayburgh DR, Turner JR, (2006) Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest 86: 191-201.
17. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, et al. (2004) The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5: 1052-1060.
18. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, et al. (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430: 694-699.
19. Lee EG, Boone DL, Chai S, Libby SL, Chien M, et al. (2000) Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289: 2350-2354.
20. Krikos A, Laherty CD, Dixit VM, (1992) Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem 267: 17971-17976.
21. Hymowitz SG, Wertz IE, (2010) A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer 10: 332-341.
22. Vereecke L, Sze M, McGuire C, Rogiers B, Chu Y, et al. (2010) Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med 207: 1513-1523.
23. Oshima N, Ishihara S, Rumi MA, Aziz MM, Mishima Y, et al. (2010) A20 is an early responding negative regulator of Toll-like receptor 5 signalling in intestinal epithelial cells during inflammation. Clin Exp Immunol 159: 185-198.
24. Kawanishi M, (2000) The Epstein-Barr virus latent membrane protein 1 (LMP1) enhances TNF alpha-induced apoptosis of intestine 407 epithelial cells: the role of LMP1 C-terminal activation regions 1 and 2. Virology 270: 258-266.
25. Arsenescu R, Bruno ME, Rogier EW, Stefka AT, McMahan AE, et al. (2008) Signature biomarkers in Crohn's disease: toward a molecular classification. Mucosal Immunol 1: 399-411.
26. Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678.
27. Vereecke L, Beyaert R, van Loo G, (2009) The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 30: 383-391.
28. Trynka G, Zhernakova A, Romanos J, Franke L, Hunt KA, et al. (2009) Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut 58: 1078-1083.
29. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, et al. (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41: 199-204.
30. Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, et al. (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40: 1062-1064.
31. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, et al. (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40: 1059-1061.
32. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, et al. (2007) Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39: 1477-1482.
33. Thomson W, Barton A, Ke X, Eyre S, Hinks A, et al. (2007) Rheumatoid arthritis association at 6q23. Nat Genet 39: 1431-1433.
34. Orozco G, Hinks A, Eyre S, Ke X, Gibbons LJ, et al. (2009) Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Hum Mol Genet 18: 2693-2699.
35. Lodolce JP, Kolodziej LE, Rhee L, Kariuki SN, Franek BS, et al. (2010) African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J Immunol 184: 7001-7009.
36. Vaarala O, Atkinson MA, Neu J, (2008) The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57: 2555-2562.
37. Meddings J, (2008) The significance of the gut barrier in disease. Gut 57: 438-440.
38. Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M, (2005) Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet 6: 376-388.
39. Turer EE, Tavares RM, Mortier E, Hitotsumatsu O, Advincula R, et al. (2008) Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20. J Exp Med 205: 451-464.
40. Beutler B, Kruys V, (1995) Lipopolysaccharide signal transduction, regulation of tumor necrosis factor biosynthesis, and signaling by tumor necrosis factor itself. J Cardiovasc Pharmacol 25 (Suppl 2): S1-8.
41. Ruemmele FM, Beaulieu JF, Dionne S, Levy E, Seidman EG, et al. (2002) Lipopolysaccharide modulation of normal enterocyte turnover by toll-like receptors is mediated by endogenously produced tumour necrosis factor alpha. Gut 51: 842-848.
42. Roulis M, Armaka M, Manoloukos M, Apostolaki M, Kollias G, (2011) Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. Proc Natl Acad Sci U S A 108: 5396-5401.
43. Clayburgh DR, Barrett TA, Tang Y, Meddings JB, Van Eldik LJ, et al. (2005) Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest 115: 2702-2715.
44. Karin M, Lin A, (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227.
45. Marchiando AM, Graham WV, Turner JR, (2010) Epithelial barriers in homeostasis and disease. Annu Rev Pathol 5: 119-144.
46. Owens SE, Graham WV, Siccardi D, Turner JR, Mrsny RJ, (2005) A strategy to identify stable membrane-permeant peptide inhibitors of myosin light chain kinase. Pharm Res 22: 703-709.
47. Weng M, Walker WA, Sanderson IR, (2007) Butyrate regulates the expression of pathogen-triggered IL-8 in intestinal epithelia. Pediatr Res 62: 542-546.
48. Wang J, Ouyang Y, Guner Y, Ford HR, Grishin AV, (2009) Ubiquitin-editing enzyme A20 promotes tolerance to lipopolysaccharide in enterocytes. J Immunol 183: 1384-1392.
49. Dixit VM, Green S, Sarma V, Holzman LB, Wolf FW, et al. (1990) Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. The Journal of biological chemistry 265: 2973-2978.
50. Lin SC, Chung JY, Lamothe B, Rajashankar K, Lu M, et al. (2008) Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20. J Mol Biol 376: 526-540.
51. Traweger A, Fang D, Liu YC, Stelzhammer W, Krizbai IA, et al. (2002) The tight junction-specific protein occludin is a functional target of the E3 ubiquitin-protein ligase itch. J Biol Chem 277: 10201-10208.
52. Shembade N, Harhaj NS, Parvatiyar K, Copeland NG, Jenkins NA, et al. (2008) The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat Immunol 9: 254-262.
53. Lui WY, Lee WM, (2005) cAMP perturbs inter-Sertoli tight junction permeability barrier in vitro via its effect on proteasome-sensitive ubiquitination of occludin. J Cell Physiol 203: 564-572.
54. Shembade N, Ma A, Harhaj EW, (2010) Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 327: 1135-1139.
55. Hutti JE, Turk BE, Asara JM, Ma A, Cantley LC, et al. (2007) IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol Cell Biol 27: 7451-7461.
56. Malynn BA, Ma A, (2009) A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme. J Exp Med 206: 977-980.
57. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, et al. (2007) Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446: 557-561.
58. Matsumoto S, Okabe Y, Setoyama H, Takayama K, Ohtsuka J, et al. (1998) Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 43: 71-78.
59. Sundberg JP, Elson CO, Bedigian H, Birkenmeier EH, (1994) Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology 107: 1726-1735.
60. Ebert EC, Hagspiel KD, (2011) Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol 45: 436-441.
61. Ebert EC, Hagspiel KD, (2011) Gastrointestinal and hepatic manifestations of rheumatoid arthritis. Dig Dis Sci 56: 295-302.
62. de Kort S, Keszthelyi D, Masclee AA, (2011) Leaky gut and diabetes mellitus: what is the link? Obes Rev 12: 449-458.
63. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG, (2005) Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33: e36.
64. Lefrancois L, Lycke N, (2001) Isolation of mouse small intestinal intraepithelial lymphocytes, Peyer's patch, and lamina propria cells. 19 Current protocols in immunology/edited by John E Coligan [et al] Chapter 3: Unit 3.
65. Fujiya M, Musch MW, Nakagawa Y, Hu S, Alverdy J, et al. (2007) The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe 1: 299-308.
66. Bishop BL, Lodolce JP, Kolodziej LE, Boone DL, Tang WJ, (2010) The role of anthrolysin O in gut epithelial barrier disruption during Bacillus anthracis infection. Biochem Biophys Res Commun 394: 254-259.